Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
0.6700
-0.0001 (-0.01%)
At close: Jan 16, 2026, 4:00 PM EST
0.6809
+0.0109 (1.63%)
After-hours: Jan 16, 2026, 7:49 PM EST
Psyence Biomedical Employees
Psyence Biomedical had 12 employees as of March 31, 2025.
Employees
12
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$328,466
Market Cap
4.28M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PBM News
- 4 days ago - Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split - GlobeNewsWire
- 6 days ago - Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity - GlobeNewsWire
- 13 days ago - Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash - GlobeNewsWire
- 4 weeks ago - Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial - GlobeNewsWire
- 5 weeks ago - Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science - GlobeNewsWire
- 7 weeks ago - Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program - GlobeNewsWire
- 2 months ago - Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets - GlobeNewsWire
- 2 months ago - Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs - GlobeNewsWire